One biotech company is turning serious heads on Wall Street, and it’s doing it with a secret weapon: artificial intelligence.
While many still brush it off as just another penny stock, its growing momentum is starting to echo the early buzz around NVIDIA. This isn’t just hype. In fact, NVIDIA itself has backed the company, holding over 7.7 million shares and powering its ultra-advanced BioHive-2 supercomputer.
That machine? It’s the most powerful AI engine owned by any drug developer today, thanks to NVIDIA’s DGX H100 systems. With it, the company is speeding up drug discovery while slashing the cost of development, something Big Pharma can’t afford to ignore.
And they haven’t. Bayer, Sanofi, Roche, Genentech, and Takeda have all partnered up, unlocking the potential for over $20 billion in future milestone payments. Then there’s the recent $700 million deal with Exscientia, another AI biotech firm, expanding its lineup to ten clinical and preclinical programs. This tiny disruptor is suddenly playing in the big leagues.
Backed by ARK Invest and stacked with over $600 million in cash, it has room to scale aggressively. Revenue is forecasted to skyrocket, from $58.8 million in 2024 to an eye-popping $263 million by 2027. That’s a 65% compound annual growth rate, and it’s just the beginning.
One of the wildest aspects? It’s developing something called a “virtual cell,” which could let scientists simulate human biology entirely digitally. Imagine the ability to test thousands of potential drug combinations in a virtual lab before ever touching a petri dish. It’s the kind of moonshot that, if it works, will redefine medicine entirely.
And despite all this, the stock is still flying under most retail investors’ radars, at least for now. But analysts are starting to catch on. According to Saqib Iqbal from Becoin.net, the stock could jump 50% or more in the next year or two as fresh clinical data and new partnerships roll out.
This isn’t just another AI company trying to ride the wave. This one is building the future of medicine from the ground up. While most are watching the usual suspects in tech, this biotech dark horse is quietly getting stronger, one algorithm, one discovery, one deal at a time.
So if you’re on the hunt for the next big breakout in AI, don’t just look at Silicon Valley. The real revolution might be happening in a lab.
- This $10 AI Stock Might Be the Next NVIDIA - June 18, 2025
- Whole Foods Closes Popular Store But Big Plans Ahead - June 17, 2025
- Saks Stops 160 Store Closures at the Last Minute - June 17, 2025
